A tweet and a chart to think about.
Was traveling in midwest y'day to see ISI clients. Huge generalist interest in biotech & pharma right now. I mean off the charts.Mark Schoenebaum (@MarkSchoenebaum) February 20, 2014
Oil prices continued their upward climb Thursday, buoyed by Wednesday's landmark OPEC agreement.
Jim Cramer says he prefers Celgene to Gilead, and Walgreens Boots Alliance to Express Scripts.
Jim Cramer remains a fan of industrials, transports, banks and domestic oil producers.
'We're seeing impressive, early responses with BB2121 without the toxicity,' says Bluebird CEO Nick Leschly.